Introduction: Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. Interferon beta (IFN-β) has been used as a treatment for MS for over two decades, but its mechanism of action is not fully understood. In this study, we aimed to investigate the role of IFN-β in the treatment of MS using a mouse model.
Methods: We used more than 50 mice with experimental autoimmune encephalomyelitis (EAE), a mouse model of MS. The mice were divided into two groups: one group received IFN-β treatment, while the other group received a placebo. We monitored the mice for clinical signs of EAE and assessed the severity of the disease using a scoring system.
Results: Our results showed that IFN-β treatment significantly reduced the severity of EAE in mice compared to the placebo group. The IFN-β-treated mice had lower clinical scores, reduced inflammation in the central nervous system, and decreased demyelination compared to the placebo group.
Conclusion: Our study suggests that IFN-β has a beneficial effect on the treatment of MS by reducing inflammation and demyelination in the central nervous system. These findings provide further support for the use of IFN-β as a treatment for MS.